Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Neurocrine Biosciences Inc — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $93.31, while Neurocrine Biosciences Inc trades at $177.42 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEF | NBIX | |
|---|---|---|
52-Week High | $97.99 | $180.55 |
52-Week Low | $93.11 | $123.10 |
Market Cap | — | $17.40B |
Sector | — | Health |
Enterprise Value | — | $16.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF (iShares 7-10 Year Treasury Bond ETF) trades at $93.54, down 0.32% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 58.33, while bond market uncertainty persists amid Federal Reserve policy speculation. Recent dividend payments of $0.31-$0.32 reflect steady income distribution to shareholders.
The outlook remains cautious as bond ETFs face pressure from potential rate hikes and inflation concerns. Investment opportunity lies in Treasury exposure for portfolio diversification, though risks include interest rate sensitivity and macroeconomic volatility affecting bond valuations.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
